Pacritinib
- Generic Name
- Pacritinib
- Brand Names
- Vonjo
- Drug Type
- Small Molecule
- Chemical Formula
- C28H32N4O3
- CAS Number
- 937272-79-2
- Unique Ingredient Identifier
- G22N65IL3O
- Background
Myelofibrosis (MF) is a rare disorder characterized by hematopoietic abnormalities and fibrosis within the bone marrow. The underlying cause of primary MF is unknown, but secondary MF can arise in patients with a history of polycythemia vera or essential thrombocythemia. While some patients may remain asymptomatic, typical symptoms of MF arise from abnormali...
- Indication
Pacritinib is indicated for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 x 10/L.
...
- Associated Conditions
- High-Risk Secondary Myelofibrosis, High risk Primary Myelofibrosis (PMF), Intermediate risk Primary Myelofibrosis (PMF), Intermediate risk Secondary Myelofibrosis
- Associated Therapies
- -
Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI)
- Conditions
- Interventions
- First Posted Date
- 2015-01-19
- Last Posted Date
- 2018-02-27
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 8
- Registration Number
- NCT02342353
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations
- Conditions
- Interventions
- First Posted Date
- 2014-12-23
- Last Posted Date
- 2019-01-25
- Lead Sponsor
- Bhavana Bhatnagar
- Target Recruit Count
- 13
- Registration Number
- NCT02323607
- Locations
- 🇺🇸
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States
Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer
- First Posted Date
- 2014-10-28
- Last Posted Date
- 2017-05-01
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 11
- Registration Number
- NCT02277093
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia
- Conditions
- Interventions
- First Posted Date
- 2014-02-05
- Last Posted Date
- 2021-11-18
- Lead Sponsor
- CTI BioPharma
- Target Recruit Count
- 311
- Registration Number
- NCT02055781
- Locations
- 🇺🇸
SCRI- Florida Cancer Specialists South Region, Fort Myers, Florida, United States
🇨🇦Saint John Regional Hospital, Saint John, New Brunswick, Canada
🇨🇦Princess Margaret Cancer Center, Toronto, Ontario, Canada
Pacritinib Versus Best Available Therapy to Treat Myelofibrosis
- Conditions
- Interventions
- First Posted Date
- 2013-01-23
- Last Posted Date
- 2020-09-29
- Lead Sponsor
- CTI BioPharma
- Target Recruit Count
- 327
- Registration Number
- NCT01773187
- Locations
- 🇺🇸
CTI Investigational Site 10004, Omaha, Nebraska, United States
🇺🇸CTI Investigational Site 10002, Scottsdale, Arizona, United States
🇦🇺CTI Investigational Site 61006, Box Hill, Australia
Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
- Conditions
- Interventions
- First Posted Date
- 2012-06-15
- Last Posted Date
- 2021-11-04
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 12
- Registration Number
- NCT01620216
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.